z-logo
Premium
Hyaluronan receptor (CD44) expression and function in human peripheral blood monocytes and alveolar macrophages
Author(s) -
Culty Martine,
O'Mara Thomas E.,
Underhill Charles B.,
Yeager Henry,
Swartz Rodney P.
Publication year - 1994
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.56.5.605
Subject(s) - cd44 , biology , microbiology and biotechnology , microgram , monoclonal antibody , in vitro , extracellular matrix , glycoprotein , antibody , immunology , biochemistry
CD44 glycoproteins are present on the surfaces of many hematopoietic cells and in some cases can bind hyaluronan, a major component of the extracellular matrix. In the present study, we have found that newly explanted human peripheral blood monocytes (PBMs) exhibit a major CD44 band of 85 kDa, whereas autologous alveolar macrophages (AM φ ) express multiple isoforms ranging from 85 to 200 kDa. Within 4 h in culture, PBMs began expressing new CD44 isoforms of 120, 150, and 180 kDa. Newly explanted AM φ specifically bound [ 3 H]hyaluronan (135 cpm/ μ g protein), but newly explanted PBMs did not. However, in vitro cultured PBM progressively acquired the ability to bind [ 3 H]hyaluronan and exhibited specific binding of hyaluronan similar to that of AM φ (113 cpm/ μ g protein) after 4 days in culture. In both cases, the binding of [ 3 H]hyaluronan was specifically inhibited by the addition of monoclonal antibody directed against CD44. AM φ readily degraded [ 3 H]hyaluronan and reached a plateau after 4 days in culture (115 cpm/ μ g protein). Newly explanted PBM exhibit no hyaluronan degradation and only a small degradative activity after 4 days in culture (6 to 11 cpm/ μ g protein). Thus, CD44 expression and function appear to change as PBM mature in vitro resembling more that found in AM φ . J. Leukoc. Biol. 56: 605–611; 1994.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here